Multi-Centre European Photopatch Test Study

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

It is known that people can develop an allergic skin reaction to a substance which is placed on the skin and then subjected to sunlight. This process is called Photocontact allergic dermatitis. It is known that people can develop Photocontact allergic dermatitis to sunscreen chemicals (filters) and also cream forms of pain-killing drugs called nonsteroidal anti-inflammatory drugs (NSAIDs).

The purpose of this study is to determine the frequency of Photocontact allergic dermatitis to 19 sunscreen filters and 5 topical NSAIDs in 1,000 European patients who present to a dermatologist with a sun-exposed site dermatitis.

Each participant will have the 24 test agents plus one control of petrolatum applied to the skin of the back for 24 or 48 hours. After removal of the substances, the area of skin will be exposed to a precise amount of ultraviolet-A light. The area is then assessed 24, 48 and 72 hours later to see if a photocontact allergic reaction has occured. This method is known as photopatch testing.

The study will run for one year, during which time it is planned to recruit 1,000 patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NHS Tayside
• Treatments: Anti-Inflammatory Agents, Non-Steroidal; Benzophenone; Diclofenac; Etofenamate; Homosalate; Ibuprofen; Ketoprofen; Octylmethoxycinnamate; Piroxicam; Salicylates; Sunscreening Agents

Criteria

Inclusion Criteria:

• Male or female aged 18 years or older.

• Have sufficient cognitive capacity to give written informed consent.

• Have an eruption on photo-exposed sites, which is to be further classified using one (or more) of the categories below:

• Known photosensitivity disease

• History of sunscreen reaction

• Sun exposed site dermatitis during summer months

• Any sun exposed site dermatitis problem

Exclusion Criteria:

• Male or female aged 17 years or younger

• Have had potent topical steroid applied to the photopatch test site on the back in the previous 5 days. (This potentially suppresses reactions which would otherwise have been visible)

• Have skin disease on the back which is too active to allow testing. (This obscures the sites of testing by making differentiation between a positive result and other skin disease difficult)

• Be prescribed systemic immunosuppressant medication (e.g. prednisolone, methotrexate, azathioprine, ciclosporin) (This potentially suppresses reactions which would otherwise have been visible)

• Be taking any photoactive medicine (for example thiazides, sulphonamide derivatives, amiodarone, fluoroquinolones, chlorpromazine, NSAIDs, quinine). (This is a relative exclusion. Many centres may wish to go ahead despite such medication).